

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

#### Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee; Notice of Meeting

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

*Name of Committee:* Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee.

*General Function of the Committee:* To provide advice and recommendations to the agency on FDA regulatory issues.

*Date and Time:* The meeting will be held on March 12, 2002, from 8 a.m. to 5 p.m.

*Location:* CDER Advisory Committee Conference Room, Rm. 1066, 5630 Fishers Lane, Rockville, MD.

*Contact Person:* Thomas H. Perez or Kimberly Littleton Topper, Center for Drug Evaluation and Research (HFD-21), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, by phone at 301-827-7001, or by e-mail at PerezT@cder.fda.gov or TopperK@cder.fda.gov, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 12542. Please call the Information Line for up-to-date information on this meeting.

*Agenda:* The subcommittee will discuss potential conflicts of interest in pediatric oncology clinical trials, off-protocol patient access to investigational drugs, and access to investigational drugs for nonclinical studies.

*Procedure:* Interested persons may present data, information, or views, orally or in writing, on issues pending before the subcommittee. Written submissions may be made to the contact person by March 4, 2002. Oral presentations from the public will be scheduled between approximately 8:15 a.m. and 12:45 p.m. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before March 4, 2002, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Persons attending FDA's advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets.

FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact Thomas H. Perez or Kimberly Littleton Topper at least 7 days in advance of the meeting.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: January 31, 2002.

**Linda A. Suydam,**

*Senior Associate Commissioner.*

[FR Doc. 02-2950 Filed 2-6-02; 8:45 am]

**BILLING CODE 4160-01-S**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

#### 2002 FDA Science Forum

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice of meeting.

The Food and Drug Administration (FDA) is announcing the following meeting: 2002 FDA Science Forum. The topic to be discussed is "FDA: Building a Multidisciplinary Foundation."

*Date and Time:* The science forum will be held on February 20 and 21, 2002, from 8:30 a.m. to 4:30 p.m.

*Location:* The science forum will be held at the Washington Convention Center, 900 Ninth St. NW., Washington, DC 20001.

*Contact:* AOAC International, Fulfillment Department, 301-924-7077, e-mail: fulfillment@aoac.org, or Donna L. Mentch, Food and Drug Administration, Office of Science (HF-33), 5600 Fishers Lane, Rockville, MD 20857, 301-827-3038, e-mail: dmentch@oc.fda.gov.

*Registration:* Attendees may register onsite on February 20 and 21, 2002. Registration and program information are also available at <http://www/aoac.org/science.htm>. Attendance will be limited; therefore, interested parties are encouraged to register early.

**SUPPLEMENTARY INFORMATION:** The 2002 FDA Science Forum will focus on the importance of FDA's many scientific and regulatory disciplines to the agency's decisionmaking process. On the first day speakers and participants will address the role of research and review in the formulation of FDA's

public health policies. The second day will feature the principles of public health surveillance and the relation of surveillance to current scientific issues, from both domestic and global perspectives.

If you need special accommodations due to a disability, please contact AOAC International at least 7 days in advance.

Dated: February 1, 2002.

**Margaret M. Dotzel,**

*Associate Commissioner for Policy.*

[FR Doc. 02-3021 Filed 2-6-02; 8:45 am]

**BILLING CODE 4160-01-S**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket No. 01D-0582]

#### Draft Guidance for Industry on Available Therapy; Availability

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing the availability of a draft guidance for industry entitled "Available Therapy." The document is intended to provide guidance to industry on the meaning of the term available therapy, as used by the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER).

**DATES:** Submit written or electronic comments on the draft guidance by April 8, 2002. General comments on agency guidance documents are welcome at any time.

**ADDRESSES:** Submit written requests for single copies of the draft guidance to the Division of Drug Information (HFD-240), Center for Drug Evaluation and Research, Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857. Send one self-addressed adhesive label to assist that office in processing your requests. Submit written comments on the draft guidance to the Dockets Management Branch (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Submit electronic comments to <http://www.fda.gov/dockets/ecomments>. See the **SUPPLEMENTARY INFORMATION** section for electronic access to the draft guidance document.

#### FOR FURTHER INFORMATION CONTACT:

For information regarding human drug products: Janet Jones, Center for Drug Evaluation and Research (HFD-